Company's everolimus-eluting platinum chromium stent now being marketed in world's second-largest DES market

SAN DIEGO, Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the third quarter of fiscal 2011 on Monday, October 31.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time), Monday, October 31, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

The teleconference call can be accessed by calling (631) 291-4555, passcode 14128534. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available through the company's website at www.volcanocorp.com.

A replay of the conference call will be available through Monday, November 7, at (404) 537-3406, and via the company's website.

Company's everolimus-eluting platinum chromium stent now being marketed in world's second-largest DES market

SAN DIEGO, Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the third
Industry News
2011-10-17T04:00:00Z

Comments